SUPPLEMENTAL FIGURE LEGENDS

Figure S1. Glucose turnover after MCPG treatment. (A) Endogenous glucose production and (B) glucose clearance were assessed two hours after infusion of vehicle (saline) or MCPG. In all panels, data are mean ± S.E.M.. (*n* =11 per group).

Figure S2. MCPG depletes hepatic acetyl CoA content through inhibiting β-oxidation of long chain fatty acids Effect of MCPG on hepatic β-oxidation. Assessed two hours after infusion of vehicle or MCPG treatment. (A) Plasma β-OHB concentration (*n* = 10 per group). (B) Hepatic MCP-formyl CoA (MCPG-CoA conjugate) concentration (*n* = 6 per group). (C) Hepatic free CoA concentration (*n* = 6 per group). (D) Hepatic acetyl-CoA concentration (*n* = 6 per group). (E**)** Hepatic short and medium chain acyl CoA concentrations (*n* = 6 per group). (F) Hepatic long chain acyl CoA concentrations (*n* = 10 per group). In all panels, data are mean ± S.E.M.. *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001, versus control.

Figure S3. Hepatic ATP:ADP ratios in MCPG treated mice. Assessed two hours after treatment. Data are mean ± S.E.M. (*n* = 9 per group).

Figure S1

A


Endogenous glucose production
[μmol//(Kg.min)]
150
100
50
0
Control
MCPG

B


Glucose clearance
[ml/(Kg.min)]
15
10
5
0
Control
MCPG

Figure S2


A
β-OHB concentration (mmol/L)
1.5
1.0
0.5
0.0
***
Control
MCPG
B
MCP-Formyl CoA (nmol/g)
80
70
60
50
40
0.5
0.4
0.3
0.2
0.1
0.0
**
Control
MCPG
C
Free CoA (nmol/g)
100
80
60
40
20
0
*
Control
MCPG
D
Hepatic acetyl CoA (nmol/g)
80
60
40
20
0
Vehicle
MCPG
E
Short/Medium chain acyl CoA (nmol/g)
25
20
15
10
5
0
*
****
****
**
C3
C4
C6
C8
C10
C12
CoA
Control
MCPG
F
Long chain CoA (nmol/g)
100
80
60
40
20
0
***
***
***
C14
C16
C18
C20
CoA
Control
MCPG

Figure S3